This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burzynski, S. R. Articles by Dolgopolov, V. Search for Related Content PubMed PubMed Citation Articles by Burzynski, S. R. Articles by Dolgopolov, V. Social Bookmarking                   What's this?

Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1

Department of Internal Medicine, Burzynski Clinic, Houston, Texas, srb{at}burzynskiclinic.com

Robert A. Weaver, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Tomasz Janicki, MD

Department of Medical Documentation, Burzynski Clinic, Houston, Texas

Barbara Szymkowski, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Gabor Jurida, MD

Department of Pediatric Oncology, Burzynski Clinic, Houston, Texas

Mohammad Khan, MD

Department of Radiology, Burzynski Clinic, Houston, Texas

Vsevolod Dolgopolov, MD

Department of Radiology, Burzynski Clinic, Houston, Texas

Primitive neuroectodermal tumors (PNETs) are usually successfully treated with craniospinal radiation and chemotherapy; however, difficulties with standard treatment can be encountered in very young children, in adult patients at high risk of complication from standard treatment, and in patients with recurrent tumors. Thirteen children, either with recurrent disease or high risk, were treated in phase II studies with antineoplastons (ANP). The median age of patients was 5 years, 7 months (range, 1-11). Medulloblastoma was diagnosed in 8 patients, pineoblastoma in 3 patients, and other PNET in 2 patients. Previous treatments included surgery in 12 patients (1 had biopsy only, suboccipital craniotomy), chemotherapy in 6 patients, and radiation therapy in 6 patients. Six patients had not received prior chemotherapy or radiation. The treatment consisted of intravenous infusions of 2 formulations of ANP, A10 and AS2-1, and was administered for an average of 20 months. The average dosage of A10 was 10.3 g/kg/d and of AS2-1 was 0.38 g/kg/d. Complete response was accomplished in 23%, partial response in 8%, stable disease in 31%, and progressive disease in 38% of cases. Six patients (46%) survived more than 5 years from initiation of ANP; 5 were not treated earlier with radiation therapy or chemotherapy. The serious side effects included single occurrences of fever, granulocytopenia, and anemia. The study is ongoing and accruing additional patients. The percentage of patients’ response is lower than for standard treatment of favorable PNET, but long-term survival in poor-risk cases and reduced toxicity makes ANP promising for very young children, patients at high risk of complication of standard therapy, and patients with recurrent tumors.

Key Words: PNET • medulloblastoma • pineoblastoma • brain tumor • long-term survival • antineoplastons • phase II study

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. R. Burzynski, T. J. Janicki, R. A. Weaver, and B. Burzynski Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma. Integr Cancer Ther, March 1, 2006; 5(1): 40 - 47. [Abstract] [PDF]